The US Centers for Medicare & Medicaid Services granted coverage for Personalis’ NeXT Personal molecular residual disease (MRD) test for surveillance in stages I–III non‑small cell lung cancer. The decision builds on clinical evidence from the TRACERx consortium and validation published in Nature Medicine demonstrating the assay’s sensitivity to detect residual disease via whole‑genome sequencing and advanced noise suppression. Personalis said Medicare coverage broadens patient access for lung‑cancer surveillance and supports its commercialization plans; the company has prior Medicare coverage decisions for breast‑cancer surveillance and partnerships to expand clinical use. The coverage could accelerate uptake of tumor‑informed MRD assays in oncology monitoring and post‑treatment decision making.